A Phase III study to assess the effect of AZD0780 on LDL-C in patients with clinical ASCVD or at risk for a first ASCVD event - AZURE-LDL

Study identifier:D7960C00012

ClinicalTrials.gov identifier:NCT07000123

EudraCT identifier:N/A

CTIS identifier:2025-520521-21-00

Will Be Recruiting

Official Title

A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event

Medical condition

cardiovascular disease

Phase

Phase 3

Healthy volunteers

Study drug

AZD0780, Placebo

Sex

All

Estimated Enrollment

2800

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 30 May 2025

Estimated Primary Completion Date: 26 Mar 2027

Estimated Study Completion Date: 26 Mar 2027

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 May 2025 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Inclusion Criteria

• ≥ 18 years of age at the time of signing the ICF
• History of clinical ASCVD or at risk for a first ASCVD event:
(a) Clinical ASCVD is defined as MI, stable or unstable angina, coronary or other arterial revascularisation, ischaemic stroke, or peripheral artery disease.
(b) A participant is considered at risk for a first ASCVD event if the participant has one or more of the following conditions: atherosclerotic vascular disease (≥ 50% stenosis in ≥ 2 coronary artery territories or in ≥ 2 vascular beds [coronary, carotid, lower extremity], diagnosed by any imaging modality), diabetes mellitus, hypertension, cigarette smoking, chronic kidney disease (moderate to severe stage), or obesity. Investigators can also use the ACC/AHA or ESC or other relevant national clinical guidelines for risk assessment to identify participants with at least moderate risk for ASCVD.
• Fasting serum LDL-C by central laboratory at screening as follows: LDL-C ≥ 55 mg/dL (≥ 1.4 mmol/L) in participants with clinical ASCVD or ≥ 70 mg/dL (≥ 1.8 mmol/L) in participants without clinical ASCVD but at risk for a first ASCVD event
• Participants should be receiving a maximally tolerated lipid lowering regimen including a maximally tolerated dose of a statin.
(a) Participants must achieve a stable dose (> 28 days) of lipid lowering therapies before screening.
(b) Participants who are judged by the treating physician not to tolerate high intensity statins (according to guidelines, typically, atorvastatin ≥ 40 mg once daily or rosuvastatin ≥ 20 mg once daily) may be included if treated with a low- or moderate intensity statin dose.
(c) Participants not receiving any statins must have documented intolerable side effects to at least 2 different statins, including one at the lowest standard dose or on a chronic medication that would prohibit the use of a statin (according to the prescribing information for the statin in question).

Exclusion Criteria

• Homozygous familial hypercholesterolaemia, known diagnosis of HeFH, LDL apheresis or plasma apheresis within 12 months prior to screening, or any other underlying known disease or condition that may interfere with interpretation of the clinical study results as judged by the Investigator.
• Any of the following laboratory values at screening:
- Calculated eGFR < 15 mL/min/1.73 m2
- AST or ALT > 3 × ULN
- TBL > 2 × ULN (except for patients with Gilberts syndrome, where TBL 3 × ULN is acceptable provided direct bilirubin < 1.5 × ULN)
- Fasting triglycerides ≥ 400 mg/dL (≥ 4.52 mmol/L)
- Creatine kinase > 5 × ULN
- Urine albumin-to-creatinine ratio ≥ 500 mg/g
• Uncontrolled type 2 diabetes mellitus defined as HbA1C ≥ 9.5% at screening
• Inadequately treated hypothyroidism defined as TSH > 1.5 ULN at screening or participants whose thyroid replacement therapy was initiated or modified within the last 3 months prior to screening
• Use of mipomersen or lomitapide (cholesterol-lowering medications) within 12 months prior to screening or planned use during the study.
• Use of gemfibrozil within 1 week prior to screening or planned use during the study.
• Use of PCSK-9 inhibitors: evolocumab/alirocumab within 12 weeks of the screening visit or planned use during the study or inclisiran within 18 months of the screening visit or planned use during the study. Any other approved PCSK-9 inhibitor use within 5 half-lives prior to the screening visit or planned use during the study.

No locations available

Arms	Assigned Interventions
Experimental: AZD0780 Participants will receive daily oral dose of AZD0780	Drug: AZD0780 Participants will receive daily oral dose of AZD0780
Placebo Comparator: Placebo Participants will receive daily oral dose of placebo	Drug: Placebo Participants will receive daily oral dose of placebo

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]